Aardvark Therapeutics, Inc. (AARD) Key Metrics
AARD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $82.7M
- Enterprise value
- $48.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
AARD key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAARD returns How much profit the business earns on the capital it uses.
AARD per-share figures Results divided by the shares outstanding at year-end.
AARD financial health Debt, liquidity and how easily interest is covered.
AARD efficiency & capital use Working capital cycle and where the cash goes.
AARD valuation history
AARD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AARD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AARD price vs earnings per share
AARD key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $286.3M | — | — | — |
| Enterprise value | $176.7M | — | — | — |
| Price / book | 2.7 | — | — | — |
| Earnings yield | −20.1% | — | — | — |
| Free cash flow yield | −19.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — |
| Share price at fiscal year-end | $13.12 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.64 | −$0.95 | −$0.34 | −$0.63 |
| Operating cash flow per share | −$2.48 | −$0.83 | −$0.27 | −$0.49 |
| Free cash flow per share | −$2.49 | −$0.84 | −$0.27 | −$0.49 |
| Cash per share | $5.04 | $3.40 | $0.47 | $0.75 |
| Book value per share | $4.89 | −$2.52 | −$1.63 | −$1.31 |
| Tangible book value per share | $4.89 | −$2.52 | −$1.63 | −$1.31 |
| Capex per share | $0.00 | $0.01 | $0.00 | $0.00 |
| Debt per share | $0.02 | $0.04 | $0.01 | $0.01 |
| Shares outstanding | 21.8M | 21.7M | 21.4M | 21.4M |
| Change in shares outstanding | +0.6% | +1.5% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −221.5% | — | — | — |
| Return on assets (ROA) | −59.2% | −46.8% | −52.8% | −80.9% |
| Return on tangible assets | −49.1% | −26.6% | −68.4% | −80.9% |
| Financial health | ||||
| Total debt | $441,000 | $779,000 | $162,000 | $262,000 |
| Cash & short-term investments | $110.0M | $73.7M | $10.0M | $16.1M |
| Net debt | −$109.6M | −$72.9M | −$9.8M | −$15.8M |
| Debt / equity | 0.00 | — | — | — |
| Debt / assets | 0.00 | 0.01 | 0.02 | 0.02 |
| Current ratio | 10.61 | 15.05 | 7.50 | 27.72 |
| Quick ratio | 10.61 | 15.05 | 7.50 | 27.72 |
| Working capital | $101.3M | $69.2M | $9.0M | $15.9M |
| Invested capital | −$3.0M | −$127.5M | −$44.6M | −$43.8M |
| Tangible asset value | $106.6M | −$54.6M | −$34.8M | −$27.9M |
| Net current asset value | $101.3M | −$58.0M | −$35.0M | −$28.2M |
| Graham net-net per share | $4.56 | −$2.70 | −$1.65 | −$1.34 |
| Capital allocation | ||||
| Share buybacks (net) | $0 | — | — | — |
| Capex / depreciation | 2.64 | 6.81 | 0.00 | 0.00 |
| Efficiency | ||||
| Days payables outstanding | 22,153.5 | 38,017.0 | 2,434.6 | 859.4 |
| Payables turnover | 0.02 | 0.01 | 0.15 | 0.42 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.2M | $1.7M | $647,000 | $259,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from AARD's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AARD valuation and financial ratios
Aardvark Therapeutics earned a return on equity of −221.5% in fiscal 2025. It ended the year with $0.4 million of debt and $110.0 million in cash and short-term investments, a net cash position of $109.6 million.
See the AARD income statement, the AARD chart for price history, or the AARD stock overview for the latest quote and news.
AARD key metrics FAQ
What is Aardvark Therapeutics's return on equity?
Aardvark Therapeutics's return on equity (ROE) was −221.5% in fiscal 2025: net income of -$57.6 million on average shareholders' equity of $26.0 million.
How much debt does Aardvark Therapeutics have?
Aardvark Therapeutics had total debt of $0.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Aardvark Therapeutics's free cash flow yield?
Aardvark Therapeutics generated -$54.3 million of free cash flow in fiscal 2025, a free cash flow yield of −19.0% on its market value at year-end ($286.3 million).
What is Aardvark Therapeutics's current ratio?
Aardvark Therapeutics's current ratio was 10.61 at the end of fiscal 2025: current assets were 10.61 times current liabilities.